Professor John Ramage

Biography

John is a Consultant in Gastroenterology, Clinical Research Director at Hampshire Hospitals NHS Foundation Trust and a Visiting Professor in the Hampshire Collaboration for Health Research and Education (HCHRE), part of the University's Health and Wellbeing Research Group. The HCHRE is an initiative that aims to link Hampshire hospitals with the University of Winchester. 

He has a background in cancer research, and is the lead clinician for the Kings Health Partners Neuroendocrine Centre for Excellence, based at Kings College London. He is Senior Lecturer at Kings College London and has a programme of research there.

He is current chair of UKINETS, the main UK organisation for improving care for NET patients. He is on the advisory board for ENETS, the equivalent European organisation. He is previous chair of the Wessex Clinical Research Network and recently stepped down from R+D Director of Hampshire Hospitals. He is Regional Advisor in Gastroenterology for the Wessex Region. He is Chief Investigator for a number of National and International Research projects.

Prof. Ramage is keen to hear from potential research students who wish to undertake postgraduate research under his supervision.

Areas of expertise

Consultant Gastroenterologist and Hepatologist specialising in biliary endoscopy and gastrointestinal and liver cancer.

Publications

Peer-reviewed journal articles

• Ramage JK. Bullet and missile wounds in Northern Ireland. J Royal Naval Med. Serv. 1982 ;68:82-86.
• Ireland A, Colin-Jones DG, Gear P, Golding PL, Ramage JK, et al. Ranitidine 150mg twice daily vs 300mg nightly in the treatment of duodenal ulcers. Lancet 1984;2:274-276.
• Colin-Jones DG, Ireland A, Gear P, Golding PL, Ramage JK et al. Reducing overnight secretion of acid to heal duodenal ulcers. Comparison of standard divided dose of ranitidine with a single dose administered at night. Am J Med 1984;77:116-22.
• Deakin M, Ramage JK, Gray SP, Billings J, Colin-Jones D, Williams JG. Smoking, gastric secretion and inhibition by H2 receptor antagonists. Lancet 1985;1:1049.
• Deakin M, Ramage J, Paul A, Gray SP, Billings J, Williams JG. Don't freeze pepsin! J Royal Naval Med Serv. 1982;68:82-86.
• Ramage JK, Denton A, Williams JG. Inhibition of food-stimulated acid secretion by misoprostol, an orally-active synthetic E1 analogue prostaglandin. British Journal of Clinical Pharmacology 1985;19:9-12.
• 7. Deakin M, Ramage JK, Paul A, Gray SP, Billings J, Williams JG. Effect of enprostil, a synthetic prostaglandin E2 on 24 hour intragastric acidity, nocturnal acid and pepsin secretion. Gut 1986;27:1054-1057.
• Williams JG, Deakin M,Ramage JK. Effect of cimetidine and pirenzepine in combination on 24-hour intragastric acidity in patients with duodenal ulceration. Gut 1986;27:428-32.
• Deakin M, Glenny HP, Ramage JK, Mills JG, Burland WL, Williams JG. Large single daily dose of histamine H2 receptor antagonist for duodenal ulcer. How much and when? A clinical pharmacology study. Gut 1987;28:566-572.
• Ramage JK, Hunt RH, Perdue MH. Changes in intestinal permability and epithelial differentiation during inflammation in the rat. Gut 1988;29:57-61.
• Jenkins RT, Ramage JK, Jones DB, Collins SM, Goodacre RL, Hunt RH. Small bowel and colonic permeability to 51Cr-EDTA in patients with active inflammatory bowel disease. Clin Invest Med 1988;11:151-155.
• Ramage JK, Stanisz A, Scicchitano R, Hunt RH, Perdue MH. Effect of immunological reactions on rat intestinal epithelium. Correlation of increased intestinal permeability to 51Cr-EDTA and ovalbumin during acute inflammation and anaphylaxis. Gastroenterology 1988;94:1368-1375.
• Perdue MH, Ramage JK, Burget D, Marshall J, Masson S. Intestinal mucosal injury is associated with mast cell activation and leukotriene generation during Nippostrongylus-induced inflammation in the rat. Digestive Diseases and Sciences 1989;34:724-731.
• Ramage JK, Hunt RH. Vindaloo and you. British Medical Journal 1989; 298:30. (Letter).
• Ramage JK, Miller ARO, Clarke PD. Acute diarrhoea in expatriates in Bangladesh. Gut 1990;31:123 (Letter)
• D'Inca R, Ramage JK,Hunt RH, Perdue MH. Antigen-induced mucosal damage and restitution in the small intestine of the immunised rat. Int Arch Allergy Appl Immunol 1990;91:270-277.
• Ramage JK, Kirkham N, Doyle T, Cairns SR. Gangliocytic paraganglioma causing obstructive jaundice treated by endoscopic stenting in a patient with neurofibromatosis and nodular regenerative hyperplasia of the liver. European Journal of Gastroenterology and Hepatology 1991;3:851-854.
• Ramage JK. Ectopic Variceal Bleeding. Gastrointestinal Endoscopy Clinics of North America 1992; 2:95-109.
• Gimson AES, Ramage JK, Panos M, Hayllar K, Harrison P, Westaby D, Williams R. Randomised controlled trial of variceal banding ligation and injection sclerotherapy for bleeding oesophageal varices. Lancet 1993;342:391-94.
• Gane E, Portmann B, Saxena R, Wong P, Ramage JK, Williams R. Nodular regenerative hyperplasia of the liver following liver transplantation. Hepatology 1994 ;20:88-94.
• Ramage JK, Hale A, Gane E et al. Persistent parvovirus B-19 infection in a liver transplant recipient; treatment with plasmapheresis. Lancet 1994;343:667-668. (letter).
• Rizzi PM, Kane PA, Ryder SD, Ramage JK, Gane E, Tan KC, Portmann B, Karani J, Williams R. Accuracy of radiology in detection of hepatocellular carcinoma before liver transplantation. Gastroenterology 1994;107:1425-1429.
• Wong P, Devlin J, Gane E, Ramage J, Portmann B, Williams R FK 506 rescue therapy for intractable liver allograft rejection Transpl Int. 1994;7 Suppl 1:S70-6.
• Uddin W, Ramage JK, , Portmann B,Wilson P, Benjamin I, Tan K-C, Williams R. Hepatic venous outflow obstruction in patients with polycystic liver disease: pathogenesis and treatment. Gut 1995;1:142-145.
• Rizzi P, Ramage JK, Portmann B, Williams R. Neoadjuvant chemotherapy after liver transplantation for hepatocellular carcinoma. Transplantation Proceedings 1994; 26 : 4168-9.
• Wong PYN, Devlin J, Gane E, Ramage J, Williams R. FK506 rescue therapy for intractable liver allograft rejection. Transplant International 1994;7:70-76.
• McKay DM, Ramage J, Rangachari PK, Perdue MH. Effect of region, temperature and neuronal blockade on sodium and 51 Cr-EDTA transport across canine gastrointestinal mucosa in-vitro. Comparative biochemistry and physiology 1994;107:711-7.
• Ramage JK, Donaghy A, Farrant JM, Iorns R, Williams R. The use of serum tumour markers for the diagnosis of cholangiocarcinoma in primary sclerosing cholangitis. Gastroenterology 1995; 108: 865-9.
• Routley D, Ramage JK, McPeake J, Tan KC, Williams R. Orthotopic Liver Transplantation in the treatment of metastatic neuroendocrine tumors. Liver transplantation and surgery 1995;1:118-121.
• Rizzi P, Ryder S , Portmann B, Ramage JK, Naoumov N Williams R. Protein overexpression in cholangiocarcinoma arising in primary sclerosing cholangitis. Gut 1996;38:265-268.
• Ramage JK, Catnach S, Williams R. Overview: The management of metastatic carcinoid tumours. Liver transplantation and surgery 1995; 1:107-110.
• Gane EJ, Tibbs CJ, Ramage JK, Portmann BC, Williams R. Ribavirin therapy for hepatitis C infection following liver transplantation. Transplant International 1995;8:61-64.
• Fox K, Ramage JK. An often forgotten treatable cause of lymphocytic meningo-encephalitis. Hospital Update.1996.
• Ramage JK, Williams R, Buxton-Thomas M. Imaging of secondary neuroendocrine tumours of the liver: Comparison of I123 Metaiodobenzylguanidine (MIBG) and In111-labelled octreotide (Octreoscan). QJM 1996;89:539-542.
  
  Gill GV, Yong A, Power E, Ramage JK. Carcinoid-associated ectopic ACTH syndrome with variable response to octreotide. Postgraduate Medical Journal 1999;75: 98-100.
• Brooklyn TN, Prouse P, Portmann B, Ramage JK. Churg-Strauss syndrome and granulomatous cholangiopathy. Eur J Gastroenterol Hepatol 2000;12:809-11
• Murphy F, Curry WJ, Heaton N, Stangou A, Buxton-Thomas M, Ramage JK. Carcinoid and neuroendocrine tumours: are we making any progress? CME journal Gastroenterology, Hepatology and Nutrition. 2001;4:63-69.
• Amarapurkar AD, Davies A, Ramage JK, Stangou AJ, Wight DG, Portmann BC. Proliferation of antigen MIB-1 in metastatic carcinoid tumours removed at liver transplantation: relevance to prognosis. Eur J Gastroenterol Hepatol 2003 Feb;15(2):139-43.
• McCarthy M, Ramage J, McNair A, Gane E, Portmann B, Pagliuca A, Rela M, Heaton N, Mufti GJ, Williams R. The clinical diversity and role of chemotherapy in lymphoproliferative disorder in liver transplant recipients. J Hepatol. 1997 Dec;27(6):1015-21
• Stangou A, Buxton-Thomas M, Ramage JK Carcinoid and neuroendocrine tumours: Are we making any progress? CME Journal Gastroenterology. 2001
• Ramage JK, Davies AH; EORTC Quality of Life Group. Measurement of quality of life in carcinoid/neuroendocrine tumours. Endocr Relat Cancer. 2003 Dec;10(4):483-6. Review.
• Mahmood A, Poller DN, Ramage JK. Are renal microgranulomas related to inflammatory tubular destruction? Journal of Clinical Pathology. 2004;57:551-551.
• Sheen CL, Lamparelli H, Milne A, Green I, Ramage JK. Clinical features, diagnosis and outcome of acute portal vein thrombosis QJM. 2000 Aug;93(8):531-4.
• Sutcliffe R, Maguire D, Ramage J, Rela M, Heaton N Management of Neuroendocrine liver metastases. American J Surgery. 2004 ;187: 39-46
• Banfield A, Green, S, Ramage JK. Neuroendocrine tumour management: a team approach. Hospital medicine 2005;66:37-42.
• Green S, Ramage JK. Small bowel carcinoid tumours. Acta endoscopica 2005;35:187-193.
• Mahmood A, Needham J , Prosser J, Mainwaring J, Trebble T, Mahy G, Ramage J. Prevalence of hyperhomocysteinaemia, activated protein C resistance and prothrombin gene mutation in inflammatory bowel disease. Eur J Gastr and Hepatol. 2005;17:739-44.
• Ramage JK, Davies A et al. Guidelines for the management of gut-related neuroendocrine tumours (including carcinoid). Gut 2005; 54: iv1-iv16.
• D'HAENS1,D. HOMMES1,. ENGELS2,F. BAERT3, L. VAN DER WAAIJ4,P. CONNOR5, J. RAMAGE6,O. DEWIT7,M. PALMEN8,D. STEPHENSON8,R. JOSEPH9 Once daily MMX mesalazine for the treatment of mild-to-moderate ulcerative colitis: a phase II, dose-ranging study Alimentary Pharmacology and Therapeutics 2006., 24, 1087–1097.
• Jensen RT Nierdele B, Mitry E, Ramage JK et al. ENETS consensus guidelines: Gastrinoma (Duodenal and Pancreatic). Neuroendocrinology 2006; 84 (3): 173-182.
• ENETS consensus guidelines in Colorectal NET. Ramage JK et al. Neuroendocrinology. 2007.
• Michael Koller (1), Neil K. Aaronson (2), Jane Blazeby (3,4), Andrew Bottomley (5), Linda Dewolf (5), Peter Fayers (6,7), Colin Johnson (8), John Ramage (9), Neil Scott (6), Karen West (10) Translation procedures for standardised quality of life questionnaires: the European Organisation for Research and Treatment of Cancer (EORTC) approach. European Journal of Cancer 2007. 43, (12), 1810-1820
• Julie Parkes, Paul Roderick, Scott Harris, Christopher Day, David Mutimer, Jane Collier, Martin Lombard, Graeme Alexander, John Ramage, Geoffrey Dusheiko, Mark Wheatley, Carol Gough, Alastair Burt, and William Rosenberg Enhanced Liver Fibrosis (ELF) test can predict clinical outcomes in patients. with chronic liver disease. Gut 2010;59:1245-1251
• J. M. Blazeby, P. Fayers, T. Conroy, O. Sezer, J. Ramage, M. Rees, Validation of the European Organization for Research and Treatment of Cancer QLQ-LMC21 questionnaire for assessment of patient-reported outcomes during treatment of colorectal liver metastases - on behalf of the European Organization for Research Treatment of Cancer (EORTC) Quality of Life Group. BJS 2009. 291-29
• A Ahmed, G Turner, B King, L Jones, D Culliford, D McCance, J Ardill, B T Johnston, G Poston, M Rees, M Buxton-Thomas, M Caplin and J K Ramage, Midgut neuroendocrine tumours with liver metastases: results of the UKINETS study. Endocrine-Related Cancer 2009; 16 (3): 885 -894 . 
• R Srirajaskanthan, D Shanmugabavan, J K Ramage Carcinoid syndrome: Easily Missed?. BMJ 2010; 341:c3941
• Kos-Kudła B, O'Toole D, Falconi M, Gross D, Klöppel G, Sundin A, Ramage J, Oberg K, Wiedenmann B, Komminoth P, Van Custem E, Mallath M, Papotti M, Caplin M;Palma de Mallorca Consensus Conference Participants. ENETS consensus guidelines for the management of bone and lung metastases from neuroendocrine tumors.Neuroendocrinology. 2010;91(4):341-50.
• John K Ramage, A Ahmed, J Ardill et al. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs) Gut 2012;61:6-32
• Development of a questionnaire (EORTC module) to measure quality of life in patients with cholangiocarcinoma and gallbladder cancer, the EORTC QLQ-BIL21. E Friend, G Yadegarfar, C Byrne, C D Johnson, O Sezer, S Pucciarelli, S P Pereira, W-C Chie, A Banfield and J K Ramage on behalf of the EORTC Quality of Life Group. Br J Cancer 2011;104: 587-592;
• Basuroy R, Srirajaskanthan R, Ramage JK. A multimodal approach to the
  management of neuroendocrine tumour liver metastases. Int J Hepatol.
  2012;2012:8191-93.
• Roberts RE, Zhao M, Whitelaw BC, Ramage J, Diaz-Cano S, le Roux CW, Quaglia A, Huang GC, Aylwin SJ. GLP-1 and Glucagon Secretion from a Pancreatic Neuroendocrine Tumor Causing Diabetes and Hyperinsulinemic Hypoglycemia. J Clin Endocrinol Metab. 2012 July 6.
• Yadegarfar G, Friend L, Jones L, Plum LM, Ardill J, Taal B, Larsson G, Jeziorski K, Kwekkeboom D, Ramage JK. Validation of the EORTC QLQ-GINET21 questionnaire for assessing quality of life of patients with gastrointestinal neuroendocrine tumours. Br J Cancer. 2013 Jan 15. doi: 10.1038/bjc.2012.560.
• Basuroy, R., Srirajaskanthan, R., Prachalias, A., Quaglia, A. and Ramage, J. K. (2014), Review article: the investigation and management of gastric neuroendocrine tumours. Aliment Pharmacol Ther, 39: 1071–1084. doi:10.1111/apt.12698
• Wu, J. Srirajaskanthan R, Ramage JK. Editorial. Rectal Neuroendocrine Tumours. Digestive Endoscopy 2014. Doi 10.1111/den.12308
• Edward M. Wolin, Barbara Jarzab, Barbro Eriksson, Thomas Walter, Christos Toumpanakis, Michael Morse, Paola Tomassetti, Matthias Weber, David Fogelman, John Ramage, Donald Poon, Jerry Huang, Michelle Hudson, Xin Zhi, Janice L. Pasieka, Abakar Mahamat, Fredrik Swahn, John Newell-Price, Was Mansoor, Kjell Öberg. A multicenter, randomized, blinded, phase 3 study of pasireotide LAR vs octreotide LAR in patients with metastatic neuroendocrine tumors (NET) with disease-related symptoms inadequately controlled by somatostatin analogs. Drug Des Devel Ther. 2015; 9: 5075–5086.
• ENETS TNM Staging Predicts Prognosis in Small Bowel Neuroendocrine Tumours.
  Srirajaskanthan R. Ahmed A. Prachialias A. Srinivasan P. Heaton N. Jervis N. Quaglia A. Vivian G. Ramage JK. Isrn Oncology Print. 2013:420795, 2013. UI: 23533809
• Marianne Pavel, Dieter Hörsch, Martyn Caplin, John Ramage, Thomas Seufferlein, Juan Valle, Phillip Banks, Pablo Lapuerta, Arthur Sands, Brian Zambrowicz, Douglas Fleming, and Bertram Wiedenmann. Telotristat Etiprate for Carcinoid Syndrome: A Single-Arm, Multicenter Trial. Journal Clinical Endocrinology and Metabolism. 2015.2014-2247
• Sebastian Kaupp-Roberts, Rajaventhan Srirajaskanthan, John K. Ramage Symptoms and quality of life in gastroenteropancreatic neuroendocrine tumours EMJ Oncol. 2015;3[1]:34-40
• Debbie L Shawcross, Arthur A Dunk, Rajiv Jalan, Gerald Kircheis, Robert J de Knegt, Wim Laleman, John K Ramage, Heiner Wedemeyer, Ian EJ Morgan. How to Diagnose and Manage Hepatic Encephalopathy: A Consensus Statement on Roles and Responsibilities Beyond the Liver Specialist. Eur Journal Gastro Hepatol. 2016;28:146-152
• R. Basuroy,R. Srirajaskanthan, A. Prachalias,A. Quaglia, J. K. Ramage. Letter: the response to somatostatin analogues in neuroendocrine tumours is influenced by Ki67 score – authors' reply. Alimentary Pharmacology and Therapeutics. 2015.doi 10.1111/apt.13390
• Basuroy, Ron; Sarker, Debashis; Quaglia, Alberto; Srirajaskanthan, Rajaventhan; Ramage, John; Personalized medicine for gastroenteropancreatic neuroendocrine tumors: a distant dream? International Journal of Endocrine Oncology 2015; 2:doi 10.2217/ije.15.9
• S D Kaupp-Roberts, G Yadegarfar, E Friend, C M O'Donnell, J W Valle, C Byrne, I Bahar, M Finch-Jones, R Gillmore, C D Johnson, S P Pereira, J K Wiggers, M Pinto, B Al-Sarireh, J K Ramage and on behalf of the EORTC Quality of Life Group. Validation of the EORTC QLQ-BIL21 questionnaire for measuring quality of life in patients with cholangiocarcinoma and cancer of the gallbladder. British Journal of Cancer 2016;115:1032-1038
• Brédart, Anne; Beaudeau, Ariane; Young, Teresa; Moura De Alberquerque Melo, Hugo; Arraras, Juan Ignacio; Friend, Liz; Schmidt, Heike; Tomaszewski, Krzysztof A; Bergenmar, Mia; Anota, Amélie; Anna Costantini,Frédéric Marchal,Iwona M. Tomaszewska,Vassilios Vassiliou,Wei-Chu Chie, José Hureaux,Thierry Conroy,John Ramage,Franck Bonnetain, Dagmara Kulis, Neil K. Aaronson, for the EORTC Quality of Life GroupThe European organization for research and treatment of cancer — satisfaction with cancer care questionnaire: revision and extended application development. Psycho‐Oncology 2016. Wiley Online Library
• Ramage, J; De Herder, Ww; Delle Fave, Gf; Ferolla, P; Ferone, D; Ito, T; Uszniewski, P; Sundin, A; Weber, W; Consensus Guidelines Update for Colorectal Neuroendocrine Neoplasms (NEN). NEUROENDOCRINOLOGY 2016;103:139-143
• Basuroy, Ron; Srirajaskanthan, Raj; Ramage, John K; Neuroendocrine Tumors. Gastroenterology Clinics of North America 2016 :45 ;3:487-507.
• Silaschi, Miriam; Barr, James; Chaubey, Sanjay; Nicou, Niki; Srirajaskanthan, Raj; Byrne, Jonathan; Ramage, John; MacCarthy, Philip; Wendler, Olaf; Optimized Outcomes Using a Standardized Approach for the Treatment of Patients with Carcinoid Heart Disease. Neuroendocrinology 2017;104:257-263
• Delle Fave, Gf; O'Toole, D; Sundin, A; Taal, B; Ferolla, P; Ramage, J; Ferone, D; Ito, T; Weber, W; ENETS Consensus Guidelines Update for Gastroduodenal Neuroendocrine Neoplasms. NEUROENDOCRINOLOGY 2016; 103:119-124
• Basuroy, R; Haji, A; Ramage, JK; Quaglia, A; Srirajaskanthan, R; Review article: the investigation and management of rectal neuroendocrine tumours. Alimentary Pharmacology & Therapeutics 2016;44:4:332-345.
• Topping M1, Gray D, Friend E, Davies A, Ramage J. A Systematic Review of Symptoms and Quality of Life Issues in Pancreatic Neuroendocrine Tumours. Neuroendocrinology. 2017 Apr 20. doi: 10.1159/000475793.
• Mills, L, Drymousis P, Vashist Y, Burdelski C, Prachalias A, Srinivasan P, Menon, K, Khan S, Cave, J, Armstrong T, Weickert M, Frilling A, RamageJK , Srirajaskanthan R. Tumor size is not a reliable criterion for resection of patients with non-secreting pancreatic neuroendocrine tumours : results of an international multicenter operative cohort. Gastroenterology 2017152, S1234-1235.